All News

guidelines.jpg (keep)

ICYMI: 2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management

Jack Cush, MD

The European Alliance of Associations for Rheumatology (EULAR) has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous recommendations.

Read Article
Sjogren_syndrome_salivary%20bx%282%29.jpg

ICYMI: B Cells at the Brink in Sjögren Disease

Jack Cush, MD

A recent issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder.

Read Article
digit.ulcer_.jpg

EULAR26: Reports on Systemic Sclerosis

EurekAlert!

In an oral abstract presentation at EULAR 2026, results were shared from a longitudinal observational analysis of the EUSTAR database. The aim was to characterise organ involvement and disease progression – and time to these events – stratified by having a modified disease activity index (mDAI) score of less than 2.5 at baseline (inactive), versus those with 2.5 or higher (active).

Read Article
awards.many_.jpg

Brenda McShan: The Creative Heart of RheumNow

Jack Cush, MD

A pivotal member of the RheumNow family, Brenda McShan, will be retiring with honors.

Read Article
RheumNow Podcast square

Generic Tofacitinib (6.26.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.

Read Article
2026 Guidelines for the Treatment of Axial Spondyloarthritis New guidelines offer clinicians and patients clearer directions on diagnostic workup, treatment selection, and long-term disease management, while emphasizing shared decision-making due to ongoing evidence gap. https://t.co/SUFnOMAUw8
Dr. John Cush RheumNow ( View Tweet)
Self-Directed Cognitive Behavioral Therapy for Chronic Pain Is self-directed cognitive behavioral therapy (CBT) when augmented with asynchronous, personalized feedback for chronic pain (CBT-CP) superior to clinician-delivered CBT-CP? https://t.co/P2DDvCiLNL https://t.co/hyAArEG6V1

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR26: Pitfalls in T2T EULAR recommends T2T strategy in the management of RA and other RMD aiming for clinical remission or low disease activity guided by frequent monitoring and prompt therapy adjustments. But real-world daily implementation in remains poorly investigated. https://t.co/V6mCcdmyJz
Dr. John Cush RheumNow ( View Tweet)
2-Gene Blood Test for Kawasaki Disease in Febrile Children JAMA Network Open has publshed that a simple 2-gene blood test may aid the earlier diagnosis of Kawasaki disease in children with febrile illnesses. https://t.co/Pwb23fOcO9 https://t.co/P6g23uJzNb

Links:

Dr. John Cush RheumNow ( View Tweet)
True or False: A 5-year retrospective study found that platelet-rich plasma injections significantly outperformed NSAIDs when given to early knee osteoarthritis patients. See if you got it right in this week's RheumIQ quiz at https://t.co/Z8XFynKJ0o. https://t.co/Eu82fctE4B

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA Review on Low Back Pain A comprehensive JAMA review synthesizes current evidence on the epidemiology, pathophysiology, clinical evaluation, and treatment of nonspecific low back pain (nsLBP), drawing on 108 publications identified from a PubMed search (2005–2026) and the https://t.co/KCa97Pi1bj
Dr. John Cush RheumNow ( View Tweet)
Prospective study of 6 newly Dx RA pts starting MTX shows MTX causes a decline in T follicular helper (Tfh) cells and plasmablasts (@ wk 3 before clin response), selectively in responders but not nonresponders. MTX shifts cellular & gene expression towards a more physiological https://t.co/scmfAAE9XA
Dr. John Cush RheumNow ( View Tweet)
#TB Infection or reactivation is Psoriasis or Psoriatic Arthritis pts taking IL-23 inhibitors is rare, rare. Literature review showed 34 studies of IL-23i in PsO had no new TB, but 1 case of LTBI reactivation. In 8 IL-23i PsA studies there were NO new TB or LTBI reactivations https://t.co/h0oe3WksK1
Dr. John Cush RheumNow ( View Tweet)
EULAR 2026: Updated Recommendations for Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases The 2026 EULAR vaccination recommendations, presented by Victoria Furer, were developed by a multinational 25-member task force that include rheumatologists, an https://t.co/L5XRcIxl5s
Dr. John Cush RheumNow ( View Tweet)
Is there a path to precision medicine in #RA? Theres a substantial unmet need. Immunoengineering is possible thru nanotechnological delivery vectors, cellular therapeutics, & biomaterial scaffolds, with compelling preclinical and early clinical support. https://t.co/gL56EOlt7p https://t.co/31IRNXckym

Links:

Dr. John Cush RheumNow ( View Tweet)
RHEUM SURVEY> When treating NON-RENAL lupus, is a drug with a "lupus nephritis indication" more likely to be used? Answer here >> https://t.co/1KridYM9n8 https://t.co/WiBhdKRxik

Links:

Dr. John Cush RheumNow ( View Tweet)

Throughout Gout Campaign Month, RheumNow is bringing together internationally recognized experts to explore the Systemic Burden of Gout through Rx Updates, QD Clinic case discussions, and expert Vlogs designed for practicing rheumatologists. New educational content will release https://t.co/ZOQQuZinQd

Dr. John Cush RheumNow ( View Tweet)
Bundibugyo virus disease (BVD) outbreak in the Congo in 2026. BV is an orthoebolavirus (not Ebola virus) species. Of the 2351 reported, 505 (22%)confirmed by PCR & 19% died. Sxs: Most 20-39 yrs, F>M, Fever (74%), GI & diarrhea (67%), anorexia, Abd pain (37%). HA (42%), SOB (34%), https://t.co/yYSmPjuiZW
Dr. John Cush RheumNow ( View Tweet)
Where are we with Biomarkers in Rheumatoid Arthritis? Biomarker interest has grown considerably in the last 2 decades, owing to advances in genetics, imaging, protein, and multiomics. Despite these advances, biomarkers as the predictive holy grail of RA therapeutics and https://t.co/ggoWx8yumZ
Dr. John Cush RheumNow ( View Tweet)
B cell Targeting in SLE Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest. https://t.co/wGaZPnXfID https://t.co/a0fNvdcrbQ

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×